This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (147)  • Contact me when this article is cited  Related Content  • Related letter  • Related articles  • Similar articles in JAMA  Topic Collections  • Menopause  • Oncology  • Breast Cancer  • Alert me on articles by topic

Christopher I. Li, MD, PhD; Kathleen E. Malone, PhD; Peggy L. Porter, MD; Noel S. Weiss, MD, DrPH; Mei-Tzu C. Tang, PhD; Kara L. Cushing-Haugen, MS; Janet R. Daling, PhD

JAMA. 2003;289:3254-3263.

Context  Women using combined estrogen and progestin hormone replacement therapy (CHRT) have an increased risk of breast cancer; however, data on use for long durations and on risk associated with patterns of use are lacking.

Objective  To evaluate relationships between durations and patterns of CHRT use and risk of breast cancer by histological type and hormone receptor status.

Design  Population-based case-control study.

Setting  Three counties in western Washington State.

Participants  Nine hundred seventy-five women 65-79 years of age diagnosed with invasive breast cancer from April 1, 1997, through May 31, 1999 (histology: 196 lobular cases, 656 ductal cases, 114 cases with other histological type, and 9 cases with an unspecified histological type; estrogen receptor (ER)/progesterone receptor (PR) status: 646 ER+/PR+ cases, 147 ER+/PR- cases, and 101 ER-/PR- cases [6 ER-/PR+ cases and 75 cases with unknown ER/PR status were not included in the analyses herein]) and 1007 population controls.

Main Outcome Measures  Risks of invasive lobular, ductal, ER+/PR+, ER+/PR-, and ER-/PR- breast carcinomas.

Results  Women using unopposed estrogen replacement therapy (ERT) (exclusive ERT use), even for 25 years or longer, had no appreciable increase in risk of breast cancer, although the associated odds ratios were not inconsistent with a possible small effect. Ever users of CHRT (includes CHRT users who also had used ERT) had a 1.7-fold (95% confidence interval [CI], 1.3-2.2) increased risk of breast cancer, including a 2.7-fold (95% CI, 1.7-4.3) increased risk of invasive lobular carcinoma, a 1.5-fold (95% CI, 1.1-2.0) increased risk of invasive ductal carcinoma, and a 2.0-fold (95% CI, 1.5-2.7) increased risk of ER+/PR+ breast cancers. The increase in risk was greatest in those using CHRT for longer durations (users for 5-14.9 years and ≥15 years had 1.5-fold [95% CI, 1.0-2.3] and 1.6-fold [95% CI, 1.0-2.6] increases in risk of invasive ductal carcinoma, respectively, and 3.7-fold [95% CI, 2.0-6.6] and 2.6-fold [95% CI, 1.3-5.3] increases in risk of invasive lobular carcinoma, respectively. Associations of similar magnitudes were seen among users of both sequential and continuous CHRT. Risks of ER+/PR- and ER-/PR- tumors were not increased by use of any form of hormone replacement therapy; however, small numbers of these tumors limited power to detect possible associations.

Conclusion  These data suggest that use of CHRT is associated with an increased risk of breast cancer, particularly invasive lobular tumors, whether the progestin component was taken in a sequential or in a continuous manner.

Author Affiliations: Division of Public Health Sciences (Drs Li, Malone, Weiss, Tang, and Daling, and Ms Cushing-Haugen) and Division of Human Biology (Dr Porter), Fred Hutchinson Cancer Research Center, Seattle, Wash; and Department of Epidemiology, School of Public Health and Community Medicine (Drs Li, Malone, Weiss, and Daling) and Department of Pathology, School of Medicine (Dr Porter), University of Washington, Seattle.

RELATED LETTER

Effects of Conjugated Equine Estrogen in Postmenopausal Women With Hysterectomy: The Women's Health Initiative Randomized Controlled Trial
The Women's Health Initiative Steering Committee
JAMA. 2004;291(14):1701-1712.
ABSTRACT | FULL TEXT  

RELATED ARTICLES

Influence of Estrogen Plus Progestin on Breast Cancer and Mammography in Healthy Postmenopausal Women: The Women's Health Initiative Randomized Trial
Rowan T. Chlebowski, Susan L. Hendrix, Robert D. Langer, Marcia L. Stefanick, Margery Gass, Dorothy Lane, Rebecca J. Rodabough, Mary Ann Gilligan, Michele G. Cyr, Cynthia A. Thomson, Janardan Khandekar, Helen Petrovitch, and Anne McTiernan
JAMA. 2003;289(24):3243-3253.
ABSTRACT | FULL TEXT  

Combined Hormone Therapy and Breast Cancer: A Single-Edged Sword
Peter H. Gann and Monica Morrow
JAMA. 2003;289(24):3304-3306.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Menopausal Hormone Therapy and Breast Cancer Phenotype: Does Dose Matter?
Garwood et al.
Ann. Surg. Oncol. 2008;15:2526-2532.
ABSTRACT | FULL TEXT  

Body Size and Risk of Luminal, HER2-Overexpressing, and Triple-Negative Breast Cancer in Postmenopausal Women
Phipps et al.
Cancer Epidemiol. Biomarkers Prev. 2008;17:2078-2086.
ABSTRACT | FULL TEXT  

Conjugated Equine Estrogen and Risk of Benign Proliferative Breast Disease: A Randomized Controlled Trial
Rohan et al.
JNCI J Natl Cancer Inst 2008;100:563-571.
ABSTRACT | FULL TEXT  

Use of Different Postmenopausal Hormone Therapies and Risk of Histology- and Hormone Receptor-Defined Invasive Breast Cancer
Fournier et al.
JCO 2008;26:1260-1268.
ABSTRACT | FULL TEXT  

Both ovarian hormones estrogen and progesterone are necessary for hormonal mammary carcinogenesis in ovariectomized ACI rats
Blank et al.
Proc. Natl. Acad. Sci. USA 2008;105:3527-3532.
ABSTRACT | FULL TEXT  

Combined hormone therapy 'increases risk of lobular breast cancer after just three years of use'
Brown
Menopause Int 2008;14:2-4.
FULL TEXT  

Timing of Menarche and First Full-Term Birth in Relation to Breast Cancer Risk
Li et al.
Am J Epidemiol 2008;167:230-239.
ABSTRACT | FULL TEXT  

Relationship between Menopausal Hormone Therapy and Risk of Ductal, Lobular, and Ductal-Lobular Breast Carcinomas
Li et al.
Cancer Epidemiol. Biomarkers Prev. 2008;17:43-50.
ABSTRACT | FULL TEXT  

Relationship between Histamine2-Receptor Antagonist Medications and Risk of Invasive Breast Cancer
Mathes et al.
Cancer Epidemiol. Biomarkers Prev. 2008;17:67-72.
ABSTRACT | FULL TEXT  

Changes in Breast Cancer Incidence Rates in the United States by Histologic Subtype and Race/Ethnicity, 1995 to 2004
Li and Daling
Cancer Epidemiol. Biomarkers Prev. 2007;16:2773-2780.
ABSTRACT | FULL TEXT  

Increased incidence of lobular breast cancer in women treated with hormone replacement therapy: implications for diagnosis, surgical and medical treatment
Biglia et al.
Endocr Relat Cancer 2007;14:549-567.
ABSTRACT | FULL TEXT  

Hormones and Breast Cancer: What's the Story?
Brinton and Lacey
Cancer Epidemiol. Biomarkers Prev. 2007;16:1697-1699.
FULL TEXT  

Critical assessment of new risk factors for breast cancer: considerations for development of an improved risk prediction model
Santen et al.
Endocr Relat Cancer 2007;14:169-187.
ABSTRACT | FULL TEXT  

Estrogen affects post-menopausal women differently than estrogen plus progestin replacement therapy
Tannen et al.
Hum Reprod 2007;22:1769-1777.
ABSTRACT | FULL TEXT  

Use of Oral Conjugated Estrogen Alone and Risk of Breast Cancer
Zhang et al.
Am J Epidemiol 2007;165:524-529.
ABSTRACT | FULL TEXT  

Oestrogens inhibit interleukin 1{beta}-mediated nitric oxide synthase expression in articular chondrocytes through nuclear factor-{kappa}B impairment
Richette et al.
Ann Rheum Dis 2007;66:345-350.
ABSTRACT | FULL TEXT  

Role of Physical Activity in Modulating Breast Cancer Risk as Defined by APC and RASSF1A Promoter Hypermethylation in Nonmalignant Breast Tissue
Coyle et al.
Cancer Epidemiol. Biomarkers Prev. 2007;16:192-196.
ABSTRACT | FULL TEXT  

Type and Duration of Exogenous Hormone Use A3ects Breast Cancer Histology
Kumar et al.
Ann. Surg. Oncol. 2007;14:695-703.
ABSTRACT | FULL TEXT  

Recreational Physical Activity and Risk of Postmenopausal Breast Cancer Based on Hormone Receptor Status
Bardia et al.
Arch Intern Med 2006;166:2478-2483.
ABSTRACT | FULL TEXT  

Risk Factors for Hormone Receptor-Defined Breast Cancer in Postmenopausal Women
Rosenberg et al.
Cancer Epidemiol. Biomarkers Prev. 2006;15:2482-2488.
ABSTRACT | FULL TEXT  

Breast Cancer Risk in Postmenopausal Women Using Estrogen-Only Therapy
Lyytinen et al.
Obstet Gynecol 2006;108:1354-1360.
ABSTRACT | FULL TEXT  

Risk of Brain Tumors Associated with Exposure to Exogenous Female Sex Hormones
Wigertz et al.
Am J Epidemiol 2006;164:629-636.
ABSTRACT | FULL TEXT  

The Science of Selective Estrogen Receptor Modulators: Concept to Clinical Practice
Jordan
Clin. Cancer Res. 2006;12:5010-5013.
FULL TEXT  

MDM2 SNP309 Accelerates Tumor Formation in a Gender-Specific and Hormone-Dependent Manner.
Bond et al.
Cancer Res. 2006;66:5104-5110.
ABSTRACT | FULL TEXT  

Unopposed estrogen therapy and the risk of invasive breast cancer.
Chen et al.
Arch Intern Med 2006;166:1027-1032.
ABSTRACT | FULL TEXT  

Relationship between Established Breast Cancer Risk Factors and Risk of Seven Different Histologic Types of Invasive Breast Cancer.
Li et al.
Cancer Epidemiol. Biomarkers Prev. 2006;15:946-954.
ABSTRACT | FULL TEXT  

Effects of Conjugated Equine Estrogens on Breast Cancer and Mammography Screening in Postmenopausal Women With Hysterectomy
Stefanick et al.
JAMA 2006;295:1647-1657.
ABSTRACT | FULL TEXT  

A prospective study of female hormone use and breast cancer among black women.
Rosenberg et al.
Arch Intern Med 2006;166:760-765.
ABSTRACT | FULL TEXT  

Effect of Obesity on Presentation of Breast Cancer
Porter et al.
Ann. Surg. Oncol. 2006;13:327-332.
ABSTRACT | FULL TEXT  

Dose and duration of hormone use: understanding the effects of combined menopausal hormones on breast cancer better, 1976-2004
McPherson and Mant
J. Epidemiol. Community Health 2005;59:1078-1079.
FULL TEXT  

Menopausal hormone therapy and risk of breast cancer: a meta-analysis of epidemiological studies and randomized controlled trials
Greiser et al.
Hum Reprod Update 2005;11:561-573.
ABSTRACT | FULL TEXT  

Breast cancer risk with postmenopausal hormonal treatment
Collins et al.
Hum Reprod Update 2005;11:545-560.
ABSTRACT | FULL TEXT  

Medroxyprogesterone Acetate Induces Cell Proliferation through Up-Regulation of Cyclin D1 Expression via Phosphatidylinositol 3-Kinase/Akt/Nuclear Factor-{kappa}B Cascade in Human Breast Cancer Cells
Saitoh et al.
Endocrinology 2005;146:4917-4925.
ABSTRACT | FULL TEXT  

Hormone replacement therapy: pathobiological aspects of hormone-sensitive cancers in women relevant to epidemiological studies on HRT: a mini-review
Dietel et al.
Hum Reprod 2005;20:2052-2060.
ABSTRACT | FULL TEXT  

Serum Sex Steroids in Premenopausal Women and Breast Cancer Risk Within the European Prospective Investigation into Cancer and Nutrition (EPIC)
Kaaks et al.
JNCI J Natl Cancer Inst 2005;97:755-765.
ABSTRACT | FULL TEXT  

Age-Specific Incidence Rates of In situ Breast Carcinomas by Histologic Type, 1980 to 2001
Li et al.
Cancer Epidemiol. Biomarkers Prev. 2005;14:1008-1011.
ABSTRACT | FULL TEXT  

Targeting the estrogen receptor to treat and prevent breast cancer
Jordan
aacrmtg 2005;2005:1457-1457.
ABSTRACT  

Estrogen, Estrogen Plus Progestin Therapy, and Risk of Breast Cancer
Colditz
Clin. Cancer Res. 2005;11:909s-917s.
ABSTRACT | FULL TEXT  

Prevention of Hormone-Related Cancers: Breast Cancer
Dunn et al.
JCO 2005;23:357-367.
ABSTRACT | FULL TEXT  

A Predictive Model for the Development of Hormone-Responsive Breast Cancer
Gorla et al.
Ann. Surg. Oncol. 2005;12:48-56.
ABSTRACT | FULL TEXT  

Risk Factors for Estrogen Receptor-Positive Breast Cancer
Hwang et al.
Arch Surg 2005;140:58-62.
ABSTRACT | FULL TEXT  

Hormone Therapy: Making Decisions in the Face of Uncertainty
Peterson et al.
Arch Intern Med 2004;164:2308-2312.
FULL TEXT  

Selective Loss of AKR1C1 and AKR1C2 in Breast Cancer and Their Potential Effect on Progesterone Signaling
Ji et al.
Cancer Res. 2004;64:7610-7617.
ABSTRACT | FULL TEXT  

Etiology of Hormone Receptor-Defined Breast Cancer: A Systematic Review of the Literature
Althuis et al.
Cancer Epidemiol. Biomarkers Prev. 2004;13:1558-1568.
ABSTRACT | FULL TEXT  

Breast Cancer
Obstet Gynecol 2004;104:11S-16S.
FULL TEXT  

Hormones and breast cancer
ESHRE Capri Workshop Group
Hum Reprod Update 2004;10:281-293.
ABSTRACT | FULL TEXT  

Effects of Conjugated Equine Estrogen in Postmenopausal Women With Hysterectomy: The Women's Health Initiative Randomized Controlled Trial
The Women's Health Initiative Steering Committee
JAMA 2004;291:1701-1712.
ABSTRACT | FULL TEXT  

Influence of HRT on prognostic factors for breast cancer: a systematic review after the Women's Health Initiative trial
Antoine et al.
Hum Reprod 2004;19:741-756.
ABSTRACT | FULL TEXT  

Geographic Excess of Estrogen Receptor-Positive Breast Cancer
Benz et al.
Cancer Epidemiol. Biomarkers Prev. 2003;12:1523-1527.
ABSTRACT | FULL TEXT  

Long term use of combined HRT doubles cancer risk
Spurgeon
BMJ 2003;327:9-9.
FULL TEXT  

Combined Hormone Therapy and Breast Cancer: A Single-Edged Sword
Gann and Morrow
JAMA 2003;289:3304-3306.
FULL TEXT